Apollo Biowellness, Inc. Announces Exclusive Distribution Deal
Apollo Biowellness (OTC Pink: KOAN) has secured an exclusive distribution agreement with Revive Regenerative, Inc. for its subsidiary Evolutionary Biologics' "Evo Bio" brand products across the United States and Canada. The distribution network includes plastic surgeons, dermatologists, med spas, and other healthcare providers.
The company anticipates significant growth in the last two quarters of 2025 and throughout 2026 as a result of this partnership. Apollo Biowellness also plans to pursue additional distribution agreements in Europe, Asia, and South America. This strategic move will allow Evolutionary Biologics to focus on developing new products and brands.
Revive Regenerative, recognized as a leader in the regenerative laser field, serves as an integrated supply chain provider for biologics and energy-based laser aesthetics, with a consumer products division established through strategic mergers and acquisitions.
Apollo Biowellness (OTC Pink: KOAN) ha ottenuto un accordo esclusivo di distribuzione con Revive Regenerative, Inc. per i prodotti del marchio "Evo Bio" della sua controllata Evolutionary Biologics negli Stati Uniti e in Canada. La rete di distribuzione comprende chirurghi plastici, dermatologi, centri medici estetici e altri operatori sanitari.
L'azienda prevede una crescita significativa negli ultimi due trimestri del 2025 e per tutto il 2026 grazie a questa collaborazione. Apollo Biowellness intende inoltre cercare ulteriori accordi di distribuzione in Europa, Asia e Sud America. Questa mossa strategica permetter脿 a Evolutionary Biologics di concentrarsi sullo sviluppo di nuovi prodotti e marchi.
Revive Regenerative, riconosciuta come leader nel campo dei laser rigenerativi, opera come fornitore integrato della catena di approvvigionamento per prodotti biologici e laser estetici basati sull鈥檈nergia, con una divisione di prodotti per il consumatore creata tramite fusioni e acquisizioni strategiche.
Apollo Biowellness (OTC Pink: KOAN) ha asegurado un acuerdo exclusivo de distribuci贸n con Revive Regenerative, Inc. para los productos de la marca "Evo Bio" de su subsidiaria Evolutionary Biologics en Estados Unidos y Canad谩. La red de distribuci贸n incluye cirujanos pl谩sticos, dermat贸logos, spas m茅dicos y otros proveedores de salud.
La compa帽铆a anticipa un crecimiento significativo en los 煤ltimos dos trimestres de 2025 y a lo largo de 2026 gracias a esta asociaci贸n. Apollo Biowellness tambi茅n planea buscar acuerdos adicionales de distribuci贸n en Europa, Asia y Sudam茅rica. Este movimiento estrat茅gico permitir谩 a Evolutionary Biologics enfocarse en desarrollar nuevos productos y marcas.
Revive Regenerative, reconocida como l铆der en el campo de los l谩seres regenerativos, act煤a como proveedor integrado de la cadena de suministro para biol贸gicos y est茅tica l谩ser basada en energ铆a, con una divisi贸n de productos para consumidores establecida a trav茅s de fusiones y adquisiciones estrat茅gicas.
Apollo Biowellness (OTC Pink: KOAN)鞚� 鞛愴殞靷� Evolutionary Biologics鞚� "Evo Bio" 敫岆灉霌� 鞝滍拡鞐� 雽�頃� Revive Regenerative, Inc.鞕� 氙戈淡 氚� 旌愲倶雼� 鞝勳棴鞐� 雽�頃� 霃呾爯 鞙犿喌 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. 鞙犿喌 雱ろ姼鞗岉伂鞐愲姅 靹表槙鞕戈臣 鞚橃偓, 頂茧秬瓿� 鞚橃偓, 氅旊敂鞀ろ寣 氚� 旮绊儉 鞚橂 鞝滉车鞛愱皜 韽暔霅╇媹雼�.
須岇偓電� 鞚� 韺岉姼雱堨嫮鞚� 韱淀暣 2025雲� 頃橂皹旮办檧 2026雲� 鞝勲皹旮办棎 靸侂嫻頃� 靹膘灔鞚� 旮半寑頃橁碃 鞛堨姷雼堧嫟. 霕愴暅 Apollo Biowellness電� 鞙犽熃, 鞎勳嫓鞎�, 雮鞐愳劀 於旉皜 鞙犿喌 瓿勳暯鞚� 於旍頃� 瓿勴殟鞛呺媹雼�. 鞚� 鞝勲灥鞝� 臁办箻電� Evolutionary Biologics臧� 鞁犾牅頀� 氚� 敫岆灉霌� 臧滊皽鞐� 歆戩頃� 靾� 鞛堧弰搿� 頃╇媹雼�.
鞛儩 霠堨澊鞝� 攵勳暭鞚� 靹犽憪欤检瀽搿� 鞚胳爼氚涬姅 Revive Regenerative電� 靸濍頃欖爜 鞝滍拡瓿� 鞐愲剤歆� 旮半皹 霠堨澊鞝� 氙胳毄 鞝滍拡鞚� 鞙勴暅 韱淀暕 瓿店笁毵� 鞝滉车鞐呾泊搿滌劀, 鞝勲灥鞝� 鞚胳垬頃╇硲鞚� 韱淀暣 靻岆箘鞛� 鞝滍拡 攵�氍胳潉 甑稌頄堨姷雼堧嫟.
Apollo Biowellness (OTC Pink : KOAN) a conclu un accord exclusif de distribution avec Revive Regenerative, Inc. pour les produits de la marque "Evo Bio" de sa filiale Evolutionary Biologics aux 脡tats-Unis et au Canada. Le r茅seau de distribution comprend des chirurgiens plasticiens, des dermatologues, des spas m茅dicaux et d'autres prestataires de soins de sant茅.
L'entreprise pr茅voit une croissance significative au cours des deux derniers trimestres de 2025 et tout au long de 2026 gr芒ce 脿 ce partenariat. Apollo Biowellness envisage 茅galement de rechercher des accords de distribution suppl茅mentaires en Europe, en Asie et en Am茅rique du Sud. Cette d茅marche strat茅gique permettra 脿 Evolutionary Biologics de se concentrer sur le d茅veloppement de nouveaux produits et marques.
Reconnu comme un leader dans le domaine des lasers r茅g茅n茅ratifs, Revive Regenerative agit en tant que fournisseur int茅gr茅 de la cha卯ne d'approvisionnement pour les produits biologiques et l'esth茅tique laser 脿 base d'茅nergie, avec une division produits grand public cr茅茅e par le biais de fusions et acquisitions strat茅giques.
Apollo Biowellness (OTC Pink: KOAN) hat eine exklusive Vertriebsvereinbarung mit Revive Regenerative, Inc. f眉r die "Evo Bio"-Markenprodukte seiner Tochtergesellschaft Evolutionary Biologics in den USA und Kanada abgeschlossen. Das Vertriebsnetz umfasst plastische Chirurgen, Dermatologen, Med Spas und andere Gesundheitsdienstleister.
Das Unternehmen erwartet aufgrund dieser Partnerschaft ein signifikantes Wachstum in den letzten beiden Quartalen 2025 und im gesamten Jahr 2026. Apollo Biowellness plant au脽erdem, weitere Vertriebsvereinbarungen in Europa, Asien und S眉damerika anzustreben. Dieser strategische Schritt erm枚glicht es Evolutionary Biologics, sich auf die Entwicklung neuer Produkte und Marken zu konzentrieren.
Revive Regenerative, anerkannt als f眉hrend im Bereich regenerativer Laser, fungiert als integrierter Lieferkettenanbieter f眉r Biologika und energie-basierte Laser盲sthetik und verf眉gt 眉ber eine Verbrauchersparte, die durch strategische Fusionen und 脺bernahmen aufgebaut wurde.
- Secured exclusive distribution agreement for US and Canada markets
- Access to established network of medical professionals and facilities
- Company projects significant growth for Q3-Q4 2025 and 2026
- Strategic focus enabled for new product development
- Potential for additional international distribution agreements
- No specific revenue projections or financial terms disclosed
- Success dependent on distributor's performance
North Bergen, New Jersey--(Newsfile Corp. - July 1, 2025) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company") announces that it has entered into an exclusive distribution sales agreement with Revive Regenerative, Inc., covering the United States and Canada for the distribution of its subsidiary Evolutionary Biologics products; the "Evo Bio" Brand. Revive Regenerative has distribution channels with Plastic Surgeons, Dermatologists, Med Spas and other providers. With the distribution agreement we expect significant growth for the last two quarters of 2025 and further significant growth in 2026.
Evolutionary Biologics Ad Campaign
To view an enhanced version of this graphic, please visit:
The Company expects to enter into additional distribution agreements for other parts of the world, Europe, Asia, South America, etc. These distribution agreements will allow Evolutionary Biologics to concentrate on the development of additional products and brands.
You can follow and contact the Company on X at .
James W. Zimbler, President, stated, "By entering into the exclusive distribution sales agreement with Revive Regenerative, and its experienced marketing and sales teams, we can expand the reach of Evo Bio and also concentrate on the development of exciting new products."
Revive Regenerative, Inc., is a leader in the regenerative laser field, and serves as the integrated supply chain backbone for biologics and energy-based laser aesthetics, and a consumer products division was formed through a series of strategic mergers, acquisitions and joint ventures.
About Apollo Biowellness, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Corporate Contact
James W. Zimbler
President/CEO/Director
[email protected]
631-806-1420
To view the source version of this press release, please visit
FAQ
What is the new distribution agreement announced by Apollo Biowellness (KOAN)?
Which markets will the KOAN distribution agreement cover?
What is the expected impact of the distribution deal on Apollo Biowellness (KOAN)?
Who are the target customers for Apollo Biowellness's Evo Bio products?
What is Revive Regenerative's role in the KOAN distribution agreement?
